REHOVOT, Israel – September 7, 2017 – Kamada Ltd. (NASDAQ and TASE: KMDA), a
plasma-derived protein therapeutics company focused on orphan indications, announced
today that Amir London, Chief Executive Officer, will provide a corporate overview at the
Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual
Healthcare Conference.
Cantor Fitzgerald Global Healthcare Conference
Date: Monday, September 25
Time: 3:00pm Eastern Time
Location: InterContinental New York Barclay Hotel, New York City, Grand Ballroom #2
Webcast: http://wsw.com/webcast/cantor6/kmda/
Ladenburg Thalmann 3rd Annual Healthcare Conference
Date: Tuesday, September 26
Time: 8:30am Eastern Time
Location: Sofitel New York Hotel, Odeon Ballroom
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and
has a commercial product portfolio and a robust late-stage product pipeline. The Company
uses its proprietary platform technology and know-how for the extraction and purification
of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified,
liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived
from human plasma with known and newly-discovered therapeutic roles given its
immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties.
The Company's flagship product is GLASSIA®, the first and only liquid, ready-to-use,
intravenous plasma-derived AAT product approved by the U.S. Food and Drug
Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership
with Baxalta (now part of Shire plc) and in other counties through local distributors. In
addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products
administered by injection or infusion, that are marketed through distributors in more than
15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and
Asia. Kamada has five late-stage plasma-derived protein products in development,
including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition,
Kamada's intravenous AAT is in development for other indications, such as type-1 diabetes,
GvHD and prevention of lung transplant rejection. Kamada's rabies immune globulin
(Human) product received FDA approval for Post-Exposure Prophylaxis against rabies
infection in August 2017. Kamada also leverages its expertise and presence in the plasmaderived
protein therapeutics market by distributing more than 10 complementary
products in Israel that are manufactured by third parties.
CONTACTS:
Gil Efron
Deputy CEO & Chief Financial Officer
IR@kamada.com
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
Bob@LifeSciAdvisors.com